Skip to main content

Table 2 Circulating tumor cells detection according to denosumab treatment and bone metastasis

From: Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer

 

Number of samples

No CTCs

CTCs

P value

Estimate (95% CI)

P value

Estimate (95% CI)

Reference

28

12 (43%)

16 (57%)

Reference

 

Bone metastasis

24

11 (46%)

13 (54%)

1.000

0.89 (0.26–3.05)

Reference

 

Bone metastasis and denosumab

20

16 (80%)

4 (20%)

0.017

0.19 (0.04–0.81)

0.030

0.22 (0.04–0.96)

  1. The table shows the number of patients with and without circulating tumor cells (CTCs) among individuals with bone metastasis who were treated or not with denosumab